CIO Bulletin

Prognos Health – Unlocking the Power of Comprehensive Patient Journey Insights and Lab Results Integration through Real-World Data

Healthcare analytics has long relied on transactional health data, serving as the bedrock for various analyses. However, this data, in isolation, presents significant analytical limitations, particularly in prognoses, clinical trials, outcomes, and commercial education. To truly enhance healthcare decision-making, it becomes imperative to encompass the entire spectrum of data stemming from the patient journey. Among these datasets, lab results emerge as the most influential.

Real-world data (RWD) holds paramount importance as it allows researchers to surpass the confines of data collected within a traditional Randomized Controlled Trial (RCT). Traditional RCTs, constrained by a controlled sample population, may yield findings limited by the characteristics of the cohort examined. Moreover, RCTs typically demand substantial investment and time for data accumulation. In contrast, RWD can be sourced from diverse cohorts or population sub-groups, providing exceptionally valuable insights.

The value of examining new medications or treatment protocols in real-world settings becomes evident, where patient behavior, co-occurring treatments, and environmental factors remain uninfluenced by RCT participation. Prognos Health emerges as a key player in the realm of real-world data, unlocking the power of data to enhance health outcomes. Serving as a leading managed RWD marketplace, Prognos accelerates the development and delivery of innovative therapies. Their platform seamlessly integrates and harmonizes lab and health records for over 325 million de-identified patients.

Prognos Health's comprehensive platform offers an integrated view of patient health, empowering researchers, payers, and providers to make informed decisions about care. Leveraging a decade of clinical and analytical expertise, Prognos Health developed a solution that transforms diagnostic and transactional data into insight-ready information. Moreover, their forward-thinking approach incorporates machine learning, allowing the platform to continuously enhance its intelligence over time. In doing so, Prognos Health stands as a transformative force in maximizing the potential of real-world data for the betterment of healthcare.

Unlocking the Power of Healthcare Data to Accelerating Value across the Commercial Lifecycle

In today's business landscape, companies find themselves inundated with data demands, perpetually seeking more assets. However, acquiring additional data has evolved into a substantial expense and burden for many. The upkeep of healthcare data is crucial to ensure it is accurate, compliant, and ready for analysis. Prognos Marketplace introduces a new and improved approach to acquiring healthcare data, offering a comprehensive solution to explore, purchase, and derive benefits from the vastest source of lab test results, closed medical claims, and Rx data.

Traditionally, the process of purchasing, integrating, and analyzing de-identified patient data for clinical and commercial purposes has been arduous, expensive, and challenging for both buyers and sellers. From contract management complexities to purchase constraints, the journey to glean patient insights for better outcomes has been riddled with obstacles.

Prognos Marketplace: Streamlining Healthcare Data Access

Prognos Marketplace uniquely consolidates harmonized lab test results from trusted sources, integrating them with extensive Rx and medical claims data. With over 45 billion health records representing 325 million de-identified patients and ongoing additions of new data sources, users can effortlessly create and refine patient cohorts and make healthcare data purchases through a single contract. All purchased data is accessible on the Datavant token, ensuring interoperability with other tokenized patient-level data. This marks a transformative approach to exploring and acquiring record-level, de-identified patient data from highly trusted sources.

Prognos Factor: Elevating Commercial Lifecycle Insights

Renowned for its data-driven lab-based solutions, Prognos now introduces Prognos Factor, a Marketplace product that includes medical and prescription claims. Leveraging a token from their partner, Datavant, Prognos Factor can seamlessly integrate any necessary data, including proprietary assets, to expedite time to insight. From research and development to growth, Prognos Factor provides a holistic view of patients and customers, supporting launch excellence and commercial success.

Empowering Tactical Efforts across the Commercial Lifecycle:

Prognos Marketplace's software offers healthcare data that can bolster tactical efforts throughout the entire commercial lifecycle. It drives clinical specificity to enhance outcomes and enables reaching patients and practitioners for earlier interventions. The platform's alerts facilitate optimized outreach to physicians before they make treatment decisions, addressing the challenges posed by increasingly elusive physicians, compounded by pandemic-driven restrictions.

Revolutionizing Pharmaceutical Omnichannel Strategies:

In a landscape where static call plans and schedule-based non-personal promotion and advertising are becoming less effective, Prognos Factor introduces near-real-time clinically-focused insights and pharmaceutical omnichannel software. This transformative approach enables reaching physicians across channels based on the timing of treatment decisions for eligible patients, ensuring relevance and timing align for more impactful engagement. Prognos Factor becomes a strategic solution, preventing resource and budget waste on non-targeted advertisements, providing an avenue for precision and effectiveness in pharmaceutical marketing.

Sundeep Bhan | Co-Founder & Chief Executive Officer

Sundeep Bhan is an accomplished serial entrepreneur committed to leveraging technology to enhance healthcare. He currently holds the position of CEO and Co-founder at Prognos Health, a company that is unlocking the power of data to improve health. Prior to this, Bhan co-founded Medsite, Inc., which attracted investment from renowned firms like JP Morgan Partners, Bain, Morgan Stanley, and Reuters. He later sold the company to WebMD in 2006.

Mr. Bhan is a Senior Advisory Board member at Consonance Capital Partners, a private equity fund, and also serves on the Board of Directors for the VIA Institute on Character. Previously, he was a non-faculty Lecturer at Wharton, where he taught Healthcare Entrepreneurship. Bhan is a highly regarded influencer in digital health and frequently speaks at industry conferences and events, such as SXSW and JP Morgan. Bhan is a proud alumnus of the University of Pennsylvania.